Health
Novartis Sells Eye Drugs to Bausch for Up to $2.5 Billion
- Deal includes upfront cash and potential milestone payments
- Novartis CEO Narasimhan has been paring low-growth businesses
This article is for subscribers only.
Novartis AG agreed to sell part of its portfolio of eye medicines to Bausch + Lomb Corp. in a deal worth as much as $2.5 billion as the Swiss pharma company focuses on developing new and more lucrative drugs.
The transaction consists of $1.75 billion in upfront cash and additional milestone payments, according to a statement Friday. It includes Xiidra, a prescription medicine for dry eye disease, that generated $487 million in sales last year.